Nurix Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 weeks.
- Recent price momentum is -34.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 17.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 5.3x | Better than 96% |
| Price / Sales | 2.4x | Better than 51% |
| P/E vs own 5-yr range | 98th pctl | Better than 5% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -340.2% | Better than 5% |
| Net margin | -314.9% | Better than 4% |
| Return on equity | -49.6% | Better than 9% |
| Return on invested capital | -49.8% | Better than 6% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -51.9% | Better than 5% |
| 6-month return | -26.6% | Better than 21% |
| 12-month return (ex latest month) | 51.2% | Better than 84% |
| Distance below 52-week high | 54.5% | Better than 15% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 7.0x | Better than 91% |
| Debt to assets | 8.1% | Better than 73% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 174.9% | Better than 93% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 13.60
- Open
- 13.40
- Day range
- 12.83 - 13.67
- Avg price
- 13.00
- Volume
- 2.43M
- Turnover
- 31.64M
- Turnover ratei
- 2.79%
- Volume ratioi
- 1.12
- Amplitudei
- 6.21%
- 52-week rangei
- 12.83 - 28.23
Valuation
- P/Ei
- -4.21
- P/E (TTM)i
- 5.29
- P/Bi
- 1.45
- EPSi
- -3.05
- Book value / shi
- 8.86
- Net profit
- -333.21M
- Net assets
- 968.28M
Share structure
- Market cap
- 1.40B
- Float capi
- 1.12B
- Shares out
- 109.25M
- Float sharesi
- 87.20M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-07-24
54.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-14.99M net over the window
Short interest
- Shares short
- 18.94M
- % of floati
- 17.33%
- Days to coveri
- 7.17
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Nurix Therapeutics (NRIX)?
Nurix Therapeutics last traded at 12.85. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Nurix Therapeutics's market cap?
About 1.40B.
What is the P/E ratio of Nurix Therapeutics?
The trailing twelve-month P/E is 5.29. The Valuation tab shows it against the stock's own five-year range.
Does Nurix Therapeutics pay a dividend?
Nurix Therapeutics does not currently pay a regular dividend.
Is Nurix Therapeutics a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 35.33, which implies 174.9% upside from the current price. This is not investment advice.
What is Nurix Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Nurix Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Nurix Therapeutics discussion 0 comments